TRIB — Trinity Biotech plc

Trinity Biotech (TRIB) Q3 2024 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Q3 2024 revenues were $15.2 million, a 3% increase year-over-year. Point-of-care revenue rose significantly by 60% to $4.3 million, driven by TrinScreen sales of approximately $2.4 million.
• Clinical Laboratory Revenue: Decreased by 9% to $10.8 million, primarily due to a 70% drop in hemoglobin product sales compared to Q3 2023.
• Gross Profit: Reported at $5.3 million with a gross margin of 35%. The margin was affected by TrinScreen sales diluting overall gross margin percentages.
• Operating Loss: Reduced to $2.6 million from $4.5 million in Q3 2023, indicating a 51% improvement.
• Net Loss: $4.8 million for the quarter, down from $6.7 million in the prior year.
• Adjusted EBITDASO: Loss of $1.4 million, an improvement from a $3.5 million loss in Q3 2023.
• Cash Position: Cash balance decreased from $5.3 million to $2.8 million, with cash used in operations at $3.6 million.

2. Strategic Updates and Business Highlights

• Continuous Glucose Monitor (CGM): The company is progressing towards the commercial launch of its next-generation CGM, designed to reduce costs and waste while enhancing user experience. A second pre-pivotal trial is underway.
• New Acquisitions: Acquired prostate cancer and preeclampsia diagnostic technologies, leveraging FDA changes to gain a competitive edge. The epiCaPture prostate cancer test and Metabolomics preeclampsia test are expected to enhance the product portfolio significantly.
• Transformation Plan: The comprehensive transformation plan is on track, focusing on cost reductions through manufacturing consolidation and offshoring. Key milestones include the transfer of rapid HIV product manufacturing to offshore partners, expected to begin in Q1 2025.

3. Forward Guidance and Outlook

• Sales Guidance: Reiterated guidance for TrinScreen sales of approximately $10 million for 2024, with expectations for over $3 million in Q4.
• Profitability Expectations: Anticipated annualized run rate EBITDASO of approximately $20 million and revenues of $75 million by Q2 2025, driven by ongoing transformation initiatives.
• New Product Revenue: The preeclampsia test is expected to generate revenue in the second half of 2025, while the prostate cancer test may contribute in 2026.

4. Bad News, Challenges, or Points of Concern

• Declining Hemoglobin Revenue: Significant year-over-year decline in hemoglobin product sales, attributed to uneven ordering patterns and reduced instrument sales.
• Cash Flow Concerns: Cash used in operations remains a concern, with a decrease in cash reserves and increased working capital outflows.
• Execution Risks: While the transformation plan is ambitious, delays in execution could impact expected profitability improvements. The highly regulated environment may slow down operational changes.

5. Notable Q&A Insights

• TrinScreen Sales: Management expects approximately $3 million in TrinScreen revenue for Q4, with sales influenced by varying ordering patterns.
• Instrument Sales: Lower instrument sales are anticipated to recover as new products are rolled out, but management is cautious about pushing sales aggressively due to past cash flow issues.
• Transformation Timeline: Most transformation initiatives are expected to be completed by the end of Q1 2025, with significant financial benefits anticipated thereafter.
• Acquisition Timelines: The preeclampsia test will be revenue-generating by late 2025, while the prostate cancer test is expected to take longer to commercialize.

Overall, TRIB is making progress in its strategic initiatives and cost reduction efforts, but faces challenges in revenue consistency and cash flow management. The company remains optimistic about future growth driven by new product launches and ongoing transformation.